Core F - Neuroimaging Core

神经成像核心项目摘要/摘要 神经成像核心是一种新提出的核心，将极大地增强 马萨诸塞州ADRC(MADRC)。成像核心将利用MADRC调查员在分子、 马蒂诺斯生物医学中心的功能、结构成像和最先进的资源 成像和马萨诸塞州综合医院的PET核心，以增强我们中心的尖端优势， 多通道成像研究。成像核心将为项目1(Hedden)和 项目2(Gomez-Isla)通过体积和功能连接性MRI和PET淀粉样蛋白成像数据 获取和分析。我们还将继续支持其他MADRC的成像组件 调查人员主导的项目，包括NIH资助的PPG、R01、K23、多个基金会赠款和未来 MADRC试点赠款。与临床和数据核心密切合作，成像核心将支持 标准化采集协议和编目存储收集的受试者的神经成像数据 MADRC纵向队列参与MADRC附属的成像研究项目。我们还将获得 少数LC患者的MRI(3T)和PET淀粉样蛋白成像 将这些数据提供给项目1和项目2，以及其他具有适当IRB的MADRC附属研究 批准。我们将促进新的PET示踪剂的实施，目前正在附属项目中进行测试， 将最近开发的用于tau、炎症和mGluR5的PET配体纳入MADRC附属研究 学习。同样，我们将促进新的核磁共振方法和分析工具的实施，例如 将功能连接性、连接体扫描仪和皮质厚度信号转换为新的和正在进行的 MADRC项目。成像核心将进一步加强MADRC对国家多中心的积极参与 具有主要神经成像组件的项目，包括ADNI、DIAN、NIFD、NIH和行业赞助 多中心临床试验，包括即将进行的ADCS抗淀粉样蛋白治疗无症状AD(A4)试验。 我们将与外联核心密切合作，领导全国教育公众和医疗保健的努力 专业人士与ADCS和合作人员讨论PET淀粉样成像的适当临床应用 ADRC就与向研究参与者披露淀粉样蛋白状态相关的重要问题进行了讨论。我们将提供 为有兴趣的年轻研究人员提供多通道图像采集和分析方面的专业知识 将神经成像纳入试点项目和职业发展提案。神经成像可能会发挥更大的作用 在未来5年内在AD临床研究中发挥重要作用。这一新的成像核心将与 现有的MADRC核心，大大增强了我们为MADRC附属机构提供前线支持的能力 影像研究，包括建议更新的两个研究项目，并将促进新的 在我们中心内部以及与其他ADC之间的协作。

NEUROIMAGING CORE PROJECT SUMMARY/ABSTRACT The Neuroimaging Core is a newly proposed Core that will greatly enhance the imaging capabilities of the Massachusetts ADRC (MADRC). The Imaging Core will leverage MADRC investigator expertise in molecular, functional, and structural imaging and the state-of-the-art resources of the Martinos Center for Biomedical Imaging and the Massachusetts General Hospital PET Core to augment our Center's strengths in cutting edge, multi-modality imaging research. The Imaging Core will provide direct support for Project 1 (Hedden) and Project 2 (Gomez-Isla) through volumetric and functional connectivity MRI and PET amyloid imaging data acquisition and analyses. We will also continue to support the imaging components of other MADRC investigator led projects, including ongoing NIH funded PPG, R01s, K23, multiple foundation grants and future MADRC pilot grants. Working closely with the Clinical and Data Cores, the Imaging Core will support standardized acquisition protocols and catalogued storage of neuroimaging data collected on subjects in the MADRC Longitudinal Cohort participating in MADRC affiliated imaging research projects. We will also acquire MRI (3T) and PET amyloid imaging on a small number of LC subjects of special interest to our center and will provide these data to Projects 1 and 2, as well as to other MADRC affiliated studies with appropriate IRB approval. We will facilitate the implementation of new PET tracers, currently being tested in affiliated projects, including recently developed PET ligands for tau, inflammation, and mGluR5 into MADRC affiliated research studies. Similarly, we will facilitate the implementation of novel MRI methods and analytic tools, such as functional connectivity, the connectome scanner, and cortical thickness signatures into new and ongoing MADRC projects. The Imaging Core will further enhance MADRC's active involvement in national multi-center projects with major neuroimaging components, including ADNI, DIAN, NIFD, NIH and industry sponsored multi-center clinical trials, including the upcoming ADCS Anti-Amyloid Treatment in Asymptomatic AD (A4) trial. We will work closely with the Outreach Core to lead national efforts to educate the public and health care professionals about the appropriate clinical use of PET amyloid imaging and with the ADCS and collaborating ADRCs on important issues related to disclosure of amyloid status to research participants. We will provide expertise on multi-modality image acquisition and analysis to young investigators interested in incorporating neuroimaging into pilot projects and career development proposals. Neuroimaging is likely to play an even more integral role in AD clinical research over the next 5 years. This new Imaging Core will work closely with the existing MADRC cores, substantially augment our ability to provide frontline support to MADRC affiliated imaging studies, including two of the research projects proposed for the renewal, and will facilitate new collaborations both within our Center and with other ADCs.